Steve Scala
Stock Analyst at TD Cowen
(2.85)
# 1,753
Out of 4,944 analysts
31
Total ratings
73.08%
Success rate
13.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Scala
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Buy | $195 → $225 | $201.47 | +11.68% | 12 | Oct 7, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Hold | $53 → $59 | $47.85 | +23.30% | 3 | Oct 7, 2024 | |
| AZN AstraZeneca | Maintains: Buy | $90 → $95 | $77.94 | +21.89% | 1 | Aug 12, 2024 | |
| MRK Merck & Co. | Upgrades: Outperform | $125 → $135 | $82.71 | +63.22% | 1 | Jan 4, 2024 | |
| PFE Pfizer | Downgrades: Market Perform | $32 | $25.16 | +27.19% | 1 | Jan 4, 2024 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $430 → $500 | $660.49 | -24.30% | 8 | May 23, 2023 | |
| NVS Novartis AG | Downgrades: Market Perform | $110 → $105 | $121.20 | -13.37% | 4 | Feb 1, 2021 | |
| RPRX Royalty Pharma | Initiates: Outperform | $55 | $36.46 | +50.85% | 1 | Jul 13, 2020 |
AbbVie
Oct 7, 2024
Maintains: Buy
Price Target: $195 → $225
Current: $201.47
Upside: +11.68%
Bristol-Myers Squibb Company
Oct 7, 2024
Maintains: Hold
Price Target: $53 → $59
Current: $47.85
Upside: +23.30%
AstraZeneca
Aug 12, 2024
Maintains: Buy
Price Target: $90 → $95
Current: $77.94
Upside: +21.89%
Merck & Co.
Jan 4, 2024
Upgrades: Outperform
Price Target: $125 → $135
Current: $82.71
Upside: +63.22%
Pfizer
Jan 4, 2024
Downgrades: Market Perform
Price Target: $32
Current: $25.16
Upside: +27.19%
Eli Lilly and Company
May 23, 2023
Maintains: Outperform
Price Target: $430 → $500
Current: $660.49
Upside: -24.30%
Novartis AG
Feb 1, 2021
Downgrades: Market Perform
Price Target: $110 → $105
Current: $121.20
Upside: -13.37%
Royalty Pharma
Jul 13, 2020
Initiates: Outperform
Price Target: $55
Current: $36.46
Upside: +50.85%